Cargando…
Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing?
PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, F...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662459/ https://www.ncbi.nlm.nih.gov/pubmed/26299921 |
_version_ | 1782403159331700736 |
---|---|
author | Peterson, Jess F. Aggarwal, Nidhi Smith, Clayton A. Gollin, Susanne M. Surti, Urvashi Rajkovic, Aleksandar Swerdlow, Steven H. Yatsenko, Svetlana A. |
author_facet | Peterson, Jess F. Aggarwal, Nidhi Smith, Clayton A. Gollin, Susanne M. Surti, Urvashi Rajkovic, Aleksandar Swerdlow, Steven H. Yatsenko, Svetlana A. |
author_sort | Peterson, Jess F. |
collection | PubMed |
description | PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, FISH and microarray studies using customized CGH and CGH+SNP designs were performed on 27 samples from patients with hematological malignancies. A comprehensive comparison of the results obtained by three methods was conducted to evaluate benefits and limitations of these techniques for clinical diagnosis. RESULTS: Overall, 89.7% of chromosomal abnormalities identified by karyotyping/FISH studies were also detectable by microarray. Among 183 acquired copy number alterations (CNAs) identified by microarray, 94 were additional findings revealed in 14 cases (52%), and at least 30% of CNAs were in genomic regions of diagnostic/prognostic significance. Approximately 30% of novel alterations detected by microarray were >20 Mb in size. Balanced abnormalities were not detected by microarray; however, of the 19 apparently “balanced” rearrangements, 55% (6/11) of recurrent and 13% (1/8) of non-recurrent translocations had alterations at the breakpoints discovered by microarray. CONCLUSION: Microarray technology enables accurate, cost-effective and time-efficient whole-genome analysis at a resolution significantly higher than that of conventional karyotyping and FISH. Array-CGH showed advantage in identification of cryptic imbalances and detection of clonal aberrations in population of non-dividing cancer cells and samples with poor chromosome morphology. The integration of microarray analysis into the cytogenetic diagnosis of hematologic malignancies has the potential to improve patient management by providing clinicians with additional disease specific and potentially clinically actionable genomic alterations. |
format | Online Article Text |
id | pubmed-4662459 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-46624592015-12-02 Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? Peterson, Jess F. Aggarwal, Nidhi Smith, Clayton A. Gollin, Susanne M. Surti, Urvashi Rajkovic, Aleksandar Swerdlow, Steven H. Yatsenko, Svetlana A. Oncotarget Research Paper: Chromosome PURPOSE: To evaluate the clinical utility, diagnostic yield and rationale of integrating microarray analysis in the clinical diagnosis of hematological malignancies in comparison with classical chromosome karyotyping/fluorescence in situ hybridization (FISH). METHODS: G-banded chromosome analysis, FISH and microarray studies using customized CGH and CGH+SNP designs were performed on 27 samples from patients with hematological malignancies. A comprehensive comparison of the results obtained by three methods was conducted to evaluate benefits and limitations of these techniques for clinical diagnosis. RESULTS: Overall, 89.7% of chromosomal abnormalities identified by karyotyping/FISH studies were also detectable by microarray. Among 183 acquired copy number alterations (CNAs) identified by microarray, 94 were additional findings revealed in 14 cases (52%), and at least 30% of CNAs were in genomic regions of diagnostic/prognostic significance. Approximately 30% of novel alterations detected by microarray were >20 Mb in size. Balanced abnormalities were not detected by microarray; however, of the 19 apparently “balanced” rearrangements, 55% (6/11) of recurrent and 13% (1/8) of non-recurrent translocations had alterations at the breakpoints discovered by microarray. CONCLUSION: Microarray technology enables accurate, cost-effective and time-efficient whole-genome analysis at a resolution significantly higher than that of conventional karyotyping and FISH. Array-CGH showed advantage in identification of cryptic imbalances and detection of clonal aberrations in population of non-dividing cancer cells and samples with poor chromosome morphology. The integration of microarray analysis into the cytogenetic diagnosis of hematologic malignancies has the potential to improve patient management by providing clinicians with additional disease specific and potentially clinically actionable genomic alterations. Impact Journals LLC 2015-07-31 /pmc/articles/PMC4662459/ /pubmed/26299921 Text en Copyright: © 2015 Peterson et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper: Chromosome Peterson, Jess F. Aggarwal, Nidhi Smith, Clayton A. Gollin, Susanne M. Surti, Urvashi Rajkovic, Aleksandar Swerdlow, Steven H. Yatsenko, Svetlana A. Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title_full | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title_fullStr | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title_full_unstemmed | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title_short | Integration of microarray analysis into the clinical diagnosis of hematological malignancies: How much can we improve cytogenetic testing? |
title_sort | integration of microarray analysis into the clinical diagnosis of hematological malignancies: how much can we improve cytogenetic testing? |
topic | Research Paper: Chromosome |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662459/ https://www.ncbi.nlm.nih.gov/pubmed/26299921 |
work_keys_str_mv | AT petersonjessf integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT aggarwalnidhi integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT smithclaytona integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT gollinsusannem integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT surtiurvashi integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT rajkovicaleksandar integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT swerdlowstevenh integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting AT yatsenkosvetlanaa integrationofmicroarrayanalysisintotheclinicaldiagnosisofhematologicalmalignancieshowmuchcanweimprovecytogenetictesting |